Drug Trial Radar · NCT03250598
Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin
Last checked: Nov 19, 2026Latest source record: Oct 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Aug 9, 2017
Primary completion
Oct 2, 2017
Study completion Oct 9, 2017
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics, safety, and effect on QTc interval of AG-348 in healthy, adult Japanese and Non-Asian subjects. The study plans to evaluate 3 cohorts of a single oral dose of AG-348 in Japanese and Non-Asian subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.
Conditions
- Healthy
- Japanese
- Non-Asian
Interventions
AG-348Drug
50 mg single-dose
AG-348Drug
5 mg single-dose
AG-348Drug
200 mg single-dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCTime frame: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
- CmaxTime frame: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West Coast Clinical Trial (WCCT) Global, Inc.
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.